<?xml version="1.0" encoding="UTF-8"?>
<p id="Par34">The morbidity and mortality of lung cancer has been the highest among all types of cancers, so it is the most common form of malignancy worldwide [
 <xref ref-type="bibr" rid="CR1">1</xref>]. Lung adenocarcinoma (LUAD) is a major pathological subtype of non-small cell lung cancer (NSCLC), which approximately accounts for 40% of lung cancer cases [
 <xref ref-type="bibr" rid="CR2">2</xref>]. Surgery, chemotherapy, radiotherapy, and targeted therapy are the conventional methods of treating patients with NSCLC; however, the prognosis of these patients has been unsatisfactory till date [
 <xref ref-type="bibr" rid="CR3">3</xref>]. Since the past decade, immune checkpoint inhibitors (ICIS) have been used to treat patients with NSCLC, and they have modified the treatment pattern of this refractory disease [
 <xref ref-type="bibr" rid="CR4">4</xref>]. Tumor-infiltrating immune cells (TIICs) have impacted the immune system and tackled abnormal biological behaviors in a complex way, so they play a key role in eliciting the bodyâ€™s response to immunotherapy [
 <xref ref-type="bibr" rid="CR5">5</xref>].
</p>
